Baker Avenue Asset Management’s Cogent Biosciences COGT Stock Holding History

Baker Avenue Asset Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-21	Closed	-$205	–	590
2023 Q3	$205	Hold	21	–	–	﹤0.01%	1589
2023 Q2	$249	Hold	21	–	–	﹤0.01%	1544
2023 Q1	$227	Hold	21	–	–	﹤0.01%	1596
2022 Q4	$243	Buy	+21	New	+$260	﹤0.01%	1527

Other funds holding COGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baker Avenue Asset Management's COGT Position: Q4 2023 in Review

Baker Avenue Asset Management sold out of Cogent Biosciences (COGT) in Q4 2023, closing a stake of 21 shares — an estimated $205 sold.

Baker Avenue Asset Management first reported a position in COGT in Q4 2022 and held it in 4 quarters. The position peaked at $249 in Q2 2023. 144 funds tracked by Wall St. Rank hold COGT as of Q4 2023.

Baker Avenue Asset Management reported no remaining Cogent Biosciences position as of Q4 2023 after selling out during the quarter.
Baker Avenue Asset Management sold 21 Cogent Biosciences shares in Q4 2023, an estimated $205.
Baker Avenue Asset Management first reported a position in Cogent Biosciences in Q4 2022 and held it in 4 quarters.
Baker Avenue Asset Management's Cogent Biosciences position peaked at $249 in Q2 2023.
144 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2023.

Based on Baker Avenue Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.